TY - JOUR T1 - Successful Treatment of Concurrent Chemoradiotherapy for Stage I Nasal NK/T Cell Lymphoma: A Report of Two Cases JF - Anticancer Research JO - Anticancer Res SP - 4403 LP - 4406 VL - 25 IS - 6C AU - YUZURU NIIBE AU - KAZUSHIGE HAYAKAWA AU - MASASHI KITANO AU - HIROMICHI ISHIYAMA AU - MEIJIN NAKAYAMA AU - KAZUO YAO AU - MAKITO OKAMOTO Y1 - 2005/11/01 UR - http://ar.iiarjournals.org/content/25/6C/4403.abstract N2 - Nasal natural killer/T cell (NK/T cell) lymphoma is a rare subtype of lymphomas, being a subtype of non-Hodgkin's lymphoma with a much worse prognosis than other subtypes. One reason for this worse prognosis is that nasal NK/T cell lymphoma is resistant to standard sequential chemoradiotherapy. Thus, we adopted concurrent chemoradiotherapy using a CHOP-like regimen for treating stage I nasal NK/T cell lymphoma. Case 1 was treated with concurrent chemoradiotherapy using 41-Gy irradiation with 12 cycles of the CHOP-like regimen (THP-CVP). Case 2 was treated with concurrent chemoradiotherapy using 50-Gy irradiation with 10 cycles of THP-CVP. In both Case 1 and Case 2, the tumors disappeared after chemoradiotherapy. The Case 1 patient is still alive with 45 months free of relapse. The Case 2 patient is also still alive with 39 months free of relapse. These results suggest that concurrent chemoradiotherapy using a CHOP-like regimen for stage I nasal NK/T cell lymphoma provided sufficient dose intensity and may be a useful treatment option. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -